Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women diagnosed with triple negative breast cancer (breast cancer is not estrogen receptor positive (ER+), progesterone receptor positive (PgR+) or human epidermal growth factor receptor positive (HER2+)~  1. Clinical stage II or stage III invasive mammary carcinoma, confirmed by histological analysis, as defined in the study protocol.~ 2. Subject's age must be greater than or equal to 18 years.~ 3. ECOG Performance Status of 0-1.~ 4. Subjects must have measurable\* tumor at the primary site. \*Measurable disease is defined as follows: Any mass that can be reproducibly measured by physical examination, mammogram, and/or ultrasound and can be accurately measured in at least one dimension (longest diameter to be recorded) as 10 mm (1 cm).~ 5. No history of prior chemotherapy for primary breast cancer.~ 6. Patients with a prior history of contralateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancer within the past 5 years.~ 7. Women may have been taking tamoxifen or raloxifene as a preventive agent prior to study entry but must have discontinued the drug for at least 21 days prior to study enrollment.~ 8. Adequate organ function, as defined by the following: a) Total bilirubin \< 2.0 times the institutional Upper Limit of Normal (ULN) b) Hepatic enzymes (AST, ALT ) ≤ 2.5 times the institutional ULN c) Serum sodium, potassium, magnesium, phosphate, and calcium levels greater than or equal to the Lower Limit of Normal (LLN). d) Serum Creatinine \< 1.5 time the institutional ULN e) Hemoglobin, Neutrophil count, Platelets, PT, PTT all Grade 0-1, as defined by the NCI CTCAE v3.0.~ 9. Ability to swallow and retain oral medications (dasatinib must be swallowed whole).~ 10. Subject must not be taking any prohibited medications, as defined in Section 6.5 of the study protocol.~ 11. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (sensitivity \< 25 IU/L) within 72 hours prior to beginning study medication.~ 12. WOCBP must agree to utilize an adequate method of contraception throughout treatment, and for at least 4 weeks after stopping study medication. 13. Signed, written informed consent, including a HIPAA form, as per institutional guidelines.~Exclusion Criteria:~1. Locally recurrent breast cancer.~2. History of prior chemotherapy for breast cancer.~3. History of malignancy requiring radiotherapy or systemic treatment within the past 5 years.~4. Presence of any concurrent medical condition that would increase the risk of toxicity, including the following: •Pleural or pericardial effusion of any grade •Uncontrolled angina •Congestive heart failure •Myocardial infarction within the past 6 months •Diagnosed congenital long QT syndrome •Any history of clinical significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes) •Prolonged QTc interval (\> 450 ms) on pre-study ECG •Uncorrectable hypokalemia or hypomagnesia •Significant bleeding disorder unrelated to cancer, including: - History of congenital bleeding disorders (e.g. von Willebrand's disease) - Acquired bleeding disorder that has been diagnosed within the past year (e.g. acquired anti-factor VIII antibodies) - Ongoing or recent (less than or equal to 3 months) significant gastrointestinal bleeding.~5. Subjects taking any prohibited medications will be excluded from study, as defined in Section 6.5 of the study protocol.~6. WOCBP who are pregnant or breastfeeding or who are unwilling to use an acceptable method of contraception for the duration of study therapy and for at least 4 weeks after cessation of study drug.~7. Active or uncontrolled infection.~8. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- All subjects take open label Dasatinib (Type: EXPERIMENTAL): Dasatinib / Sprycel 100 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy